Levobeta C Retard (Levodopa, Carbidopa Monohydrate)

Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine, replenishing deficient neurotransmitter levels. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa outside the brain and increasing the amount that reaches central nervous system receptors.

The specific dose and dosing schedule of Levobeta C Retard are determined by the prescribing clinician based on the patient’s disease stage, response to therapy, and tolerability. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for Levobeta C Retard in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levobeta C Retard combines levodopa with carbidopa, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it provides more potent symptom relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Store Levobeta C Retard at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture and direct sunlight to maintain product stability throughout its shelf life.

Levobeta C Retard is taken orally, usually with a glass of water. It is formulated as a modified‑release tablet designed to release levodopa gradually, and it should be swallowed whole without crushing or chewing unless otherwise directed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), psychiatric disturbances such as hallucinations or psychosis, severe orthostatic hypotension, and rare cardiac arrhythmias. Patients should be monitored closely for these events, and any concerning symptoms should prompt immediate medical evaluation.

Levobeta C Retard is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors or those with narrow‑angle glaucoma unless specifically advised by a physician.